CNSP
CNS Pharmaceuticals, Inc.
1W: -6.2%
1M: -28.2%
3M: -66.9%
YTD: -56.8%
1Y: -95.0%
3Y: -100.0%
5Y: -100.0%
$2.29
+0.12 (+5.53%)
After Hours: $2.42 (+0.12, +5.46%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3M
52W Range2.057-45.84
Volume37,224
Avg Volume45,132
Beta0.46
Dividend—
Analyst Ratings
Company Info
CEORami Levin
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2019-11-08
Websitecnspharma.com
2100 West Loop South
Houston, TX 77027
US
Houston, TX 77027
US
800 946 9185
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Faulkner Eric | A-Award | 9,500 | — | 2026-03-02 |
| Faulkner Eric | 0 | — | 2026-03-02 | |
| O'Loughlin Steve | A-Award | 9,500 | — | 2026-03-02 |
| O'Loughlin Steve | 0 | — | 2026-03-02 | |
| Keyes Jeffry R. | A-Award | 1,517 | $12.48 | 2025-11-17 |